ANGPTL3 (Angiopoietin-Like 3) Preferentially Resides on High-Density Lipoprotein in the Human Circulation, Affecting Its Activity

被引:2
|
作者
Kraaijenhof, Jordan M. [1 ]
Tromp, Tycho R. [1 ]
Nurmohamed, Nick S. [1 ,2 ]
Reeskamp, Laurens F. [1 ]
Langenkamp, Marije [3 ]
Levels, Johannes H. M. [3 ]
Boekholdt, S. Matthijs [2 ]
Wareham, Nicholas J. [4 ]
Hoekstra, Menno [5 ]
Stroes, Erik S. G. [1 ]
Hovingh, G. Kees [1 ]
Grefhorst, Aldo [3 ]
机构
[1] Univ Amsterdam, Locat AMC, Dept Vasc Med, Med Ctr, Amsterdam, Netherlands
[2] Univ Amsterdam, Locat AMC, Dept Cardiol, Med Ctr, Amsterdam, Netherlands
[3] Univ Amsterdam, Locat AMC, Dept Expt Vasc Med, Med Ctr, Amsterdam, Netherlands
[4] Med Res Council MRC, Epidemiol Unit, Cambridge, England
[5] Leiden Univ, Leiden Acad Ctr Drug Res, Div BioTherapeut, Leiden, Netherlands
来源
关键词
adipocytes; atherosclerosis; cholesterol; drug therapy/hypolipidemic drugs; lipase/lipoprotein; triglycerides; FAMILIAL COMBINED HYPOLIPIDEMIA; BROWN ADIPOSE-TISSUE; APOLIPOPROTEIN-E; EPIC-NORFOLK; IN-VITRO; MUTATIONS; PLASMA; GENE; CHOLESTEROL; PROTEIN-3;
D O I
10.1161/JAHA.123.030476
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: ANGPTL3 (angiopoietin- like protein 3) is an acknowledged crucial regulator of lipid metabolism by virtue of its inhibitory effect on lipoprotein lipase and endothelial lipase. It is currently unknown whether and to which lipoproteins ANGPTL3 is bound and whether the ability of ANGPTL3 to inhibit lipase activity is affected by binding to lipoproteins.METHODS AND RESULTS: Incubation of ultracentrifugation-isolated low-density lipoprotein (LDL) and high-density lipoprotein (HDL) fractions from healthy volunteers with recombinant ANGPTL3 revealed that ANGPTL3 associates with both HDL and LDL particles ex vivo. Plasma from healthy volunteers and a patient deficient in HDL was fractionated by fast protein liquid chromatography, and ANGPTL3 distribution among lipoprotein fractions was measured. In healthy volunteers, approximate to 75% of lipoprotein-associated ANGPTL3 resides in HDL fractions, whereas ANGPTL3 was largely bound to LDL in the patient deficient in HDL. ANGPTL3 activity was studied by measuring lipolysis and uptake of H-3-trioleate by brown adipocyte T37i cells. Unbound ANGPTL3 did not suppress lipase activity, but when given with HDL or LDL, ANGPTL3 suppressed lipase activity by 21.4 +/- 16.4% (P=0.03) and 25.4 +/- 8.2% (P=0.006), respectively. Finally, in a subset of the EPIC (European Prospective Investigation into Cancer) Norfolk study, plasma HDL cholesterol and amount of large HDL particles were both positively associated with plasma ANGPTL3 concentrations. Moreover, plasma ANGPTL3 concentrations showed a positive association with incident coronary artery disease (odds ratio, 1.25 [95% CI, 1.01- 1.55], P=0.04).CONCLUSIONS: Although ANGPTL3 preferentially resides on HDL, its activity was highest once bound to LDL particles.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Angiopoietin-Like Protein 3 (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia
    Chen, Pei-Yi
    Gao, Wan-Yun
    Liou, Je-Wen
    Lin, Ching-Yen
    Wu, Ming-Jiuan
    Yen, Jui-Hung
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (14)
  • [2] ANGIOPOIETIN-LIKE 3 (ANGPTL3) RESIDES ON HDL AND LDL WITH THE LATTER FORM HAVING THE HIGHEST LIPASE INHIBITORY ACTIVITY
    Tromp, T. R.
    Reeskamp, L. F.
    Langenkamp, M.
    Levels, J. H. M.
    Hoekstra, M.
    Hovingh, G. K.
    Grefhorst, A.
    [J]. ATHEROSCLEROSIS, 2022, 355 : E42 - E42
  • [3] Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol
    Xu, Yu-Xin
    Redon, Valeska
    Yu, Haojie
    Querbes, William
    Pirruccello, James
    Liebow, Abigail
    Deik, Amy
    Trindade, Kevin
    Wang, Xiao
    Musunuru, Kiran
    Clish, Clary B.
    Cowan, Chad
    Fizgerald, Kevin
    Rader, Daniel
    Kathiresan, Sekar
    [J]. ATHEROSCLEROSIS, 2018, 268 : 196 - 206
  • [4] Atypical angiopoietin-like protein that regulates ANGPTL3
    Quagliarini, Fabiana
    Wang, Yan
    Kozlitina, Julia
    Grishin, Nick V.
    Hyde, Rhonda
    Boerwinkle, Eric
    Valenzuela, David M.
    Murphy, Andrew J.
    Cohen, Jonathan C.
    Hobbs, Helen H.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (48) : 19751 - 19756
  • [5] The Angiopoietin-like Proteins ANGPTL3 and ANGPTL4 Inhibit Lipoprotein Lipase Activity through Distinct Mechanisms
    Shan, Lu
    Yu, Xuan-Chuan
    Liu, Ziye
    Hu, Yi
    Sturgis, Lydia T.
    Miranda, Maricar L.
    Liu, Qingyun
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (03) : 1419 - 1424
  • [6] Structure and Function of Angiopoietin-like Protein 3 (ANGPTL3) in Atherosclerosis
    Lu, Xinjie
    [J]. CURRENT MEDICINAL CHEMISTRY, 2020, 27 (31) : 5159 - 5174
  • [7] Identification of a New Functional Domain in Angiopoietin-like 3 (ANGPTL3) and Angiopoietin-like 4 (ANGPTL4) Involved in Binding and Inhibition of Lipoprotein Lipase (LPL)
    Lee, E-Chiang
    Desai, Urvi
    Gololobov, Gennady
    Hong, Seokjoo
    Feng, Xiao
    Yu, Xuan-Chuan
    Gay, Jason
    Wilganowski, Nat
    Gao, Cuihua
    Du, Ling-Ling
    Chen, Joan
    Hu, Yi
    Zhao, Sharon
    Kirkpatrick, Laura
    Schneider, Matthias
    Zambrowicz, Brian P.
    Landes, Greg
    Powell, David R.
    Sonnenburg, William K.
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (20) : 13735 - 13745
  • [8] ROLE OF HUMAN ANGIOPOIETIN-LIKE PROTEIN 3 (ANGPTL3) GLYCOSYLATION IN THE PROTEIN SECRETION AND STABILITY
    Burza, M. A.
    Pirazzi, C.
    Maglio, C.
    Molinaro, A.
    Corradini, S. Ginanni
    Romeo, S.
    [J]. ATHEROSCLEROSIS SUPPLEMENTS, 2011, 12 (01) : 3 - 4
  • [9] Angiopoietin-like protein 3 (ANGPTL3) deficiency and familial combined hypolipidemia
    Tarugi, Patrizia
    Bertolini, Stefano
    Calandra, Sebastiano
    [J]. JOURNAL OF BIOMEDICAL RESEARCH, 2019, 33 (02): : 73 - 81
  • [10] Human Angiopoietin-like Protein 3/ANGPTL3 Antibodies: Adding to the Armamentarium in the Management of Dyslipidemia
    Wiggins, Barbara S.
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2021, 78 (05) : e631 - e640